TRIQUILAR 28 TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
30-05-2017
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
LEVONORGESTREL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL; ETHINYL ESTRADIOL; LEVONORGESTREL
Tillgänglig från:
BAYER INC
ATC-kod:
G03AB03
INN (International namn):
LEVONORGESTREL AND ESTROGEN
Dos:
125MCG; 30MCG; 40MCG; 50MCG; 30MCG; 75MCG
Läkemedelsform:
TABLET
Sammansättning:
LEVONORGESTREL 125MCG; ETHINYL ESTRADIOL 30MCG; ETHINYL ESTRADIOL 40MCG; LEVONORGESTREL 50MCG; ETHINYL ESTRADIOL 30MCG; LEVONORGESTREL 75MCG
Administreringssätt:
ORAL
Enheter i paketet:
28
Receptbelagda typ:
Prescription
Terapiområde:
CONTRACEPTIVES
Produktsammanfattning:
Active ingredient group (AIG) number: 0618648001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2007-03-08
Produktens egenskaper
_TRIQUILAR Product Monograph _
_Page 1 of 54_
PRODUCT MONOGRAPH
PR
TRIQUILAR
® 21
PR
TRIQUILAR
® 28
0.05 mg levonorgestrel and 0.03 mg ethinyl estradiol tablets
0.075 mg levonorgestrel and 0.04 mg ethinyl estradiol tablets
0.125 mg levonorgestrel and 0.03 mg ethinyl estradiol tablets
USP
Oral Contraceptive
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Revision:
May 26, 2017
Submission Control No: 202824
© 2017, Bayer Inc.
® TM see www.bayer.ca/tm-mc
_TRIQUILAR Product Monograph _
_Page 2 of 54_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND ADMINISTRATION
..............................................................................23
OVERDOSAGE
................................................................................................................26
ACTION AND CLINICAL PHARMACOLOGY
............................................................27
STORAGE AND STABILITY
..........................................................................................30
SPECIAL HANDLING INSTRUCTIONS
.......................................................................30
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
.....................................
Läs hela dokumentet
